Document is current
Any future updates will be listed below
-
Authors
Martín-Arana, Jorge https://orcid.org/0000-0003-4554-5760
Gimeno-Valiente, Francisco https://orcid.org/0000-0003-0544-9459
Henriksen, Tenna Vesterman https://orcid.org/0000-0002-8541-1735
García-Micó, Blanca https://orcid.org/0000-0002-9370-7966
Martínez-Castedo, Belén https://orcid.org/0009-0002-3629-8526
Gambardella, Valentina
Martínez-Ciarpaglini, Carolina
Palomar, Brenda
Huerta, Marisol
Camblor, Daniel G.
García Bartolomé, Miguel
Carbonell-Asins, Juan Antonio
Frydendahl, Amanda https://orcid.org/0000-0001-9552-5421
Gotchalck, Kåre Andersson https://orcid.org/0000-0001-5119-2231
Fleitas, Tania
Tébar-Martínez, Roberto
Moro, David
Pla, Vicente
Pérez-Santiago, Leticia https://orcid.org/0000-0002-3090-8330
Martín-Arévalo, José
Casado, David
García-Botello, Stephanie https://orcid.org/0000-0001-6921-4902
Espí, Alejandro
Roselló, Susana https://orcid.org/0000-0003-3915-4130
Roda, Desamparados
Andersen, Claus Lindbjerg https://orcid.org/0000-0002-7406-2103
Cervantes, Andrés https://orcid.org/0000-0003-3806-3691
Tarazona, Noelia https://orcid.org/0000-0003-4888-1655
- License Information
-
More Information
Article History
Received: 8 March 2024
Accepted: 25 March 2025
First Online: 29 April 2025
Competing interests
: A.C. declares institutional research funding from Genentech, Merck Serono, BMS, MSD, Roche, Beigene, Bayer, Servier, Lilly, Natera, Novartis, Takeda, Astellas and Fibrogen and advisory board or speaker fees from Merck Serono, Roche, Servier, Takeda and Astellas. N.T. declares advisory board or speaker fees from Merck Serono, Servier, Pfizer, Natera and Guardant Health. M.H. declares advisory board and speaker fees from Servier. T.F. declares institutional research funding from Genentech, Adapt Immune, Roche, Beigene, Astelas, BMS, Daichii Sanyo and Amgen and speaker fees from Astrazeneca, Amgen, Bayer, BMS, Lilly, MSD and Servier. V.G. declares advisory board fees from Boehringer Ingelheim and institutional research funding from Bayer, Boehringer, Roche, Genentech, Merck Serono, Beigene, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Natera, Sierra Oncology, AstraZeneca, Medimmune, BMS and MSD. S.R. declares personal fees as an invited speaker from Amgen, MSD and Servier, advisory board fees from Amgen, Servier and Sirtex and institutional funding from Ability Pharmaceuticals, Astellas, G1 Therapeutics, Hutchinson, Menarini, Mirati, Novartis, Pfizer, Pierre Fabre, Roche and Seagen. C.L.A. declares institutional research funding from Natera, C2i Genomics and BioRad Laboratories. V.P.M. reports consultancy for Johnson&Johnson and Baxter, has received honorarium for speaking at symposia and workshops by Johnson&Johnson, Medtronic and Braun Medical and has received support for attending meetings by Takeda. J. Martín-Arévalo reports consultancy for Baxter and has received honorarium for speaking at workshops by Johnson&Johnson and Medtronic. D.M. has received honorarium for speaking at symposia and workshops by Johnson&Johnson and Medtronic and support for attending meetings by Sanofi. S.G.-B., A.E. and L.P.-S. have received honorarium for educational courses by Johnson&Johnson, Marina Garcés Albir and Dixie Huntley. C.M.-C. declares advisory board or speaker fees from MSD, Astelas and BMS. The other authors declare no competing interests.
